皮膚科領域におけるS-1108の基礎的・臨床的検討

DOI

書誌事項

タイトル別名
  • Laboratory and clinical studies on S-1108 in bacterial skin infection

抄録

We studied S-1108, a new oral cephem, for its clinical efficacy and safety, of thirty-five patients with bacterial skin infection were given S-1108 orally in a daily dose of 225mg-450mg for 5-1 days and skin concentrations were measured in twenty-four patients (75mg-12 patients and 150 mg-12 patients, single dose), and obtained the following results.<BR>1) Skin concentrations of S-1108 were 0.06-4.48μg/g at 1°17'-3°18'after oral administration of 75mg and 0.23-0.77μg/g at 1°00'-2°38' after 150mg.<BR>2) The clinical effects of S-1108 in the 35 patients with bacterial skin infections were excellent in 17, good in 12, fair in 4, poor in 2, and the efficacy rate was 82.8%.<BR>3) The rate of eradication of isolated organisms thought to be the cause of the infectious skin disease was 100% for S. aureus and 85.7% overall.<BR>4) There were no side effects or abnormal laboratory findings.

収録刊行物

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ